Download to Learn More
AAV manufacturing via transient transfection continues to face a yield ceiling that limits scalability and drives high cost of goods, especially for high-dose systemic programs. As pipelines expand, improving productivity without introducing additional complexity has become a critical focus for development and manufacturing teams.
Emerging approaches to optimizing production biology can translate directly into fewer batches and/or reduced scale to meet the same demand. These strategies help reduce footprint, consumables, and QC burden while expanding effective capacity.
Access this whitepaper to learn how:
- How advances in Rep/Cap design can improve production efficiency without requiring changes to the therapeutic payload, ITRs, or capsid amino acid sequence
- What’s driving higher titers across multiple serotypes (AAV5, AAV6, AAV8, AAV9, AAVrh10), and how to evaluate impact while maintaining comparability across key quality attributes
- How improving yields without vector redesign may offer a more scalable, lower regulatory-risk pathway to accelerate development timelines and optimize manufacturing economics
- And more
Offered Free by: Catalent Pharma Solutions
See All Resources from: Catalent Pharma Solutions
